Is Treatment With Hydroxychloroquine Effective in Surfactant Protein C Deficiency

Published on May 1, 2013in Archivos De Bronconeumologia4.957
· DOI :10.1016/J.ARBR.2012.08.013
Ingrid Rabach6
Estimated H-index: 6
(UniTS: University of Trieste),
Furio Poli4
Estimated H-index: 4
(UniTS: University of Trieste)
+ 3 AuthorsEgidio Barbi25
Estimated H-index: 25
(UniTS: University of Trieste)
a b s t r a c t We present the case of two twin brothers with surfactant protein C deficiency who were treated with hydroxychloroquine for three years, with apparent success. The exact physiopathology of this disease is not known and there is no specific treatment for it. There is merely news from a few previous descriptions in the literature about the use of hydroxychloroquine for surfactant protein C deficiency with satisfac- tory results. Two years after the treatment was withdrawn, the twins were evaluated once again: they presented no new infections, growth and general state were normal and chest CT showed a notable addi- tional reduction in the interstitial pneumopathy. These data seem to cast some doubt on the efficacy of hydroxychloroquine, and they suggest that the clinical improvement was simply the natural evolution of the disease.
📖 Papers frequently viewed together
201 Citations
8 Citations
111 Citations
#1Guillaume Thouvenin (French Institute of Health and Medical Research)H-Index: 13
#2Rola Abou TaamH-Index: 11
Last. Ralph Epaud (University of Paris)H-Index: 26
view all 14 authors...
Study objectives To present diagnosis and treatment modalities of children with interstitial lung disease associated with frequent or rare surfactant protein C gene ( SFTPC ) mutation. Patients Twenty-two children with chronic lung disease associated with SFTPC mutation in a heterozygous form. Results Mutations located in the BRICHOS domain (‘BRICHOS domain’ group) were identified in six children, whereas 16 children carried mutations located outside the BRICHOS domain (‘non-BRICHOS domain’ grou...
111 CitationsSource
#1Rodney Tehrani (Loyola University Medical Center)H-Index: 6
#2Rochella A. Ostrowski (Loyola University Medical Center)H-Index: 7
Last. Walter M. Jay (Loyola University Medical Center)H-Index: 14
view all 4 authors...
This review summarizes the current literature regarding the ocular complications of hydroxychloroquine. Hydroxychloroquine has been used since the 1950s for the treatment of various rheumatic and dermatologic diseases. Hydroxychloroquine can cause ocular toxicity, with the most serious being an irreversible retinopathy. At the present time, no “gold standard” exists for identification of the ocular toxicity prior to its development. This has led to controversy regarding the recommendations for o...
100 CitationsSource
To the Editor: We wish to report initial success in treating a boy with surfactant protein C deficiency. The patient was first admitted to the hospital at five months of age with severe respiratory...
85 CitationsSource
#1Jeffrey A. Whitsett (Cincinnati Children's Hospital Medical Center)H-Index: 93
#2Timothy E. WeaverH-Index: 26
Pulmonary surfactants consist of phospholipids and the hydrophobic proteins surfactant protein B and surfactant protein C. These surfactants keep the alveoli in the lung open to the atmosphere. Mutations in the genes encoding these proteins cause a variety of pulmonary syndromes. The pulmonary diseases associated with some of these mutations exemplify the consequences of the accumulation of misfolded proteins in tissue.
588 CitationsSource
#1Raouf S. AminH-Index: 52
#2Susan E. WertH-Index: 59
Last. Jeffrey A. WhitsettH-Index: 93
view all 8 authors...
Abstract Objective: To determine the contribution of surfactant protein abnormalities to the development of chronic lung injury in a familial form of interstitial lung disease. Study design: An 11-year-old girl, her sister, and their mother who were diagnosed with chronic interstitial lung disease underwent laboratory investigation of surfactant protein expression in bronchoalveolar lavage fluid and lung biopsy specimens. Nineteen patients with idiopathic pulmonary fibrosis and 9 patients who we...
186 CitationsSource
#1Lawrence M. Nogee (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 55
#2Alston E. Dunbar (Johns Hopkins University)H-Index: 3
Last. Jeffrey A. Whitsett (UC: University of Cincinnati)H-Index: 93
view all 6 authors...
Interstitial lung diseases are a heterogeneous group of disorders that are poorly understood at a molecular level.1,2 The cause is often unknown, and the histologic diagnoses used in adults may represent different disease processes in children.3–5 For example, cases of desquamative interstitial pneumonitis reported in infants are often more severe and refractory to treatment than those reported in adults.6,7 Many of these cases probably represent chronic pneumonitis of infancy.8,9 The lungs in p...
861 CitationsSource
#1Richard E. BehrmanH-Index: 26
#2Robert M. KliegmanH-Index: 3
Last. Hal B. JensonH-Index: 30
view all 3 authors...
The dedication of this volume states: To the physicians and nurses who care for children in many different circumstances throughout the world and who, by their efforts and commitment, make the world a better place for children. I have used the Nelson Textbook of Pediatrics since its third edition. It remains a source of amazement to me, as I witness the evolution of the book and of the knowledge that dictates its scope. From the days when a textbook was written by 1 or 2 authors, we have progres...
718 Citations
Cited By9
#2Majeda S. Hammoud (Kuniv: Kuwait University)H-Index: 12
view all 5 authors...
BACKGROUND Pulmonary surfactant is a complex mixture of lipids and specific proteins that stabilizes the alveoli at the end of expiration. Mutations in the gene coding for the triphosphate binding cassette transporter A3 (ABCA3), which facilitates the transfer of lipids to lamellar bodies, constitute the most frequent genetic cause of severe neonatal respiratory distress syndrome and chronic interstitial lung disease in children. Hydroxychloroquine can be used as an effective treatment for this ...
#1Oded Breuer (UWA: University of Western Australia)H-Index: 12
#2André Schultz (UWA: University of Western Australia)H-Index: 15
Summary Interstitial lung disease in children (chILD) comprises a range of different rare diseases. There is limited evidence for the treatment of chILD and no randomised clinical trials of treatment have been undertaken. Most treatments are therefore prescribed off-label based on expert opinion. The off-label nature of prescription of drugs for chILD highlights the importance of a solid understanding of the side effects to facilitate risk-benefit assessment. The European Respiratory Society chI...
8 CitationsSource
#1Whitney Eldridge (WashU: Washington University in St. Louis)H-Index: 2
#2Qunyuan Zhang (WashU: Washington University in St. Louis)H-Index: 39
Last. Jennifer A. Wambach (WashU: Washington University in St. Louis)H-Index: 17
view all 8 authors...
Objective To compare outcomes of infants and children who underwent lung transplantation for genetic disorders of surfactant metabolism ( SFTPB , SFTPC , ABCA3 , and NKX2-1 ) over 2 epochs (1993-2003 and 2004-2015) at St Louis Children's Hospital. Study design We retrospectively reviewed clinical characteristics, mortality, and short- and long-term morbidities of infants (transplanted at 1 year; n = 16) and compared outcomes by age at transplantation (infants vs children) and by epoch of transpl...
25 CitationsSource
#1Melissa Kaori Silva Litao (Boston Children's Hospital)H-Index: 2
#2Don Hayes (Nationwide Children's Hospital)H-Index: 35
Last. Lokesh GuglaniH-Index: 12
view all 6 authors...
Abstract Mutations of the Surfactant Protein C (SPC) gene (SFTPC) have been associated with childhood interstitial lung disease (chILD) with variable age of onset, severity of lung disease, and outcomes. We report a novel mutation in SFTPC [c.435G->A, p.(Gln145)] that was associated with onset of symptoms in early infancy, progressive respiratory failure with need for prolonged mechanical ventilatory support, and eventual lung transplant at 1 year of age. While the mutation was not predicted to ...
17 CitationsSource
#1María Beatriz Milet (Clínica Alemana)
#2Patricia Mena N (UC: Pontifical Catholic University of Chile)H-Index: 5
view all 4 authors...
Introduction Congenital surfactant deficiency is a condition infrequently diagnosed in newborns. A clinical case is presented of surfactant protein B deficiency. A review is performed on the study, treatment and differential diagnosis of surfactant protein deficiencies and infant chronic interstitial lung disease. Case report The case is presented of a term newborn that developed respiratory distress, recurrent pulmonary opacification, and a transient response to the administration of surfactant...
#1Avigdor Hevroni (HUJI: Hebrew University of Jerusalem)H-Index: 5
#2Aliza Goldman (HUJI: Hebrew University of Jerusalem)H-Index: 2
Last. Chaim Springer (HUJI: Hebrew University of Jerusalem)H-Index: 28
view all 3 authors...
Summary Pulmonary function testing is a vital tool in evaluation and management of adult ILD patients and is rarely overlooked during workup. However, there is paucity of data regarding its usefulness in management of infants with suspected interstitial lung disease. In this paper, we present the contribution of infant pulmonary function testing (iPFT) to the management of two infants with biopsy confirmed chronic pneumonitis of infancy due to surfactant protein C mutation. We have productively ...
6 CitationsSource
Pulmonary surfactant is essential for life as it lines the alveoli to lower surface tension, thereby preventing atelectasis during breathing. Surfactant is enriched with a relatively unique phospholipid, termed dipalmitoylphosphatidylcholine, and four surfactant-associated proteins, SP-A, SP-B, SP-C, and SP-D. The hydrophobic proteins, SP-B and SP-C, together with dipalmitoylphosphatidylcholine, confer surface tension–lowering properties to the material. The more hydrophilic surfactant component...
99 CitationsSource
#1Sarah Braun (LMU: Ludwig Maximilian University of Munich)H-Index: 1
#2Marion Ferner (University of Mainz)H-Index: 7
Last. Matthias Griese (LMU: Ludwig Maximilian University of Munich)H-Index: 68
view all 4 authors...
Summary Hydroxychloroquine (HCQ) is one of the drugs frequently used for the treatment of interstitial lung disease (ILD) in children (chILD). This use is off-label and studies to analyze the effect and safety of HCQ in chILD are lacking. Therefore, a literature research on the usage of chloroquine (CQ) and HCQ in these conditions was done. Eighty-five case reports and small series in the period from 1984 to 2013 were identified in which children with different diagnoses of ILD were treated with...
23 CitationsSource